Letrozole

Letrozole 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Solid Tumor、HR+/HER2- Breast Cancer、HR+, HER2-, Advanced Breast Cancer、CCNE1 Amplification。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Letrozole 研究

• Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy

  不适用招募中中国香港NCT05487092

• Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients

  不适用招募中VietnamNCT06239376

• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  I 期 / II 期招募中美国加拿大Czechia丹麦NCT07288359

• Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

  II 期招募中美国NCT04614194

• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  II 期招募中美国NCT01042379

• Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism

  不适用招募中EgyptNCT06041204

• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  III 期招募中美国Argentina澳大利亚比利时NCT06757634

• SNF Platform Study of HR+/ HER2-advanced Breast Cancer

  II 期招募中中国NCT05594095

• Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

  III 期招募中意大利NCT05601700

• Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

  II 期 / III 期招募中中国NCT05744687

• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

  I 期 / II 期招募中中国NCT07708194

• Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS

  不适用招募中BangladeshNCT07255911

• Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

  II 期招募中美国NCT05472792

• A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

  III 期招募中中国NCT05851014

• Letrozole Plus Misoprostol Versus Misoprostol Alone for Treating Women With Missed Miscarriage

  IV 期招募中PakistanNCT07160855

• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

  II 期招募中瑞典NCT05900206

• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

  II 期招募中中国NCT07180160

• A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

  II 期招募中美国ArgentinaBrazil加拿大NCT07054190

• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

  III 期招募中比利时Cyprus法国德国NCT05512364

• Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

  IV 期招募中德国瑞士NCT05362760

• A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors

  I 期 / II 期招募中中国NCT06555068

• Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

  II 期招募中中国NCT05228951

• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国比利时法国德国NCT05768139

• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

  III 期招募中美国加拿大中国香港日本NCT04852887

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。